{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["42(1)"],"submitter":["Lang M"],"funding":["National Institutes of Health"],"pubmed_abstract":["<h4>Background</h4>MiT-Renal Cell Carcinoma (RCC) is characterized by genomic translocations involving microphthalmia-associated transcription factor (MiT) family members TFE3, TFEB, or MITF. MiT-RCC represents a specific subtype of sporadic RCC that is predominantly seen in young patients and can present with heterogeneous histological features making diagnosis challenging. Moreover, the disease biology of this aggressive cancer is poorly understood and there is no accepted standard of care therapy for patients with advanced disease. Tumor-derived cell lines have been established from human TFE3-RCC providing useful models for preclinical studies.<h4>Methods</h4>TFE3-RCC tumor derived cell lines and their tissues of origin were characterized by IHC and gene expression analyses. An unbiase"],"journal":["Journal of experimental & clinical cancer research : CR"],"pagination":["99"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10127337"],"repository":["biostudies-literature"],"pubmed_title":["High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma."],"pmcid":["PMC10127337"],"pubmed_authors":["Lang M","Vocke CD","James A","Wangsa D","Ried T","Difilippantonio S","Srinivasan R","Ferrer M","Wilson KM","Moris F","Linehan WM","Klumpp-Thomas C","Wei D","Chen L","Schmidt LS","Sourbier C","Merino MJ","Thomas CJ","Ricketts CJ","Gibbs BK","Guha R","Itkin Z","Crooks DR","Yang Y","Karim B","Zhang X","McKnight C"],"additional_accession":[]},"is_claimable":false,"name":"High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma.","description":"<h4>Background</h4>MiT-Renal Cell Carcinoma (RCC) is characterized by genomic translocations involving microphthalmia-associated transcription factor (MiT) family members TFE3, TFEB, or MITF. MiT-RCC represents a specific subtype of sporadic RCC that is predominantly seen in young patients and can present with heterogeneous histological features making diagnosis challenging. Moreover, the disease biology of this aggressive cancer is poorly understood and there is no accepted standard of care therapy for patients with advanced disease. Tumor-derived cell lines have been established from human TFE3-RCC providing useful models for preclinical studies.<h4>Methods</h4>TFE3-RCC tumor derived cell lines and their tissues of origin were characterized by IHC and gene expression analyses. An unbiase","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Apr","modification":"2025-04-26T17:26:30.514Z","creation":"2025-04-06T15:30:21.731Z"},"accession":"S-EPMC10127337","cross_references":{"pubmed":["37095531"],"doi":["10.1186/s13046-023-02667-4"]}}